Working… Menu

Bevacizumab in Recurrent Grade II and III Glioma (TAVAREC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01164189
Recruitment Status : Completed
First Posted : July 16, 2010
Last Update Posted : February 28, 2019
Hoffmann-La Roche
Information provided by (Responsible Party):
European Organisation for Research and Treatment of Cancer - EORTC